Cargando…

The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma

Background: To compare the efficacy and safety of long- versus short-interval of transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (HCC) patients. Methods: This retrospective analysis enrolled 574 patients with unresectable HCC who underwent at least two sessions of TAC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Zhi-Wen, He, Wei, Zheng, Yun, Zou, Ru-Hai, Liu, Wen-Wu, Zhang, Yuan-Ping, Wang, Chen-Wei, Wang, Yong-Jin, Yuan, Yi-Chuan, Li, Bin-Kui, Yuan, Yun-Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218788/ https://www.ncbi.nlm.nih.gov/pubmed/30410605 http://dx.doi.org/10.7150/jca.24250

Ejemplares similares

Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma
por: Li, Binkui, et al.
Publicado: (2021)

Predictive factors for the benefit of triple‐drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma
por: He, MinKe, et al.
Publicado: (2019)

Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma with Child-Pugh B7
por: Jiang, Jian-Qiang, et al.
Publicado: (2023)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review
por: Manjunatha, Nisha, et al.
Publicado: (2022)

The Effect of Alcohol Consumption in Unresectable Hepatocellular Carcinoma with Transarterial Chemoembolization
por: Sun, Bo, et al.
Publicado: (2022)

Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Long, Jianwu, et al.
Publicado: (2023)

Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma
por: Wan, Xuying, et al.
Publicado: (2016)

Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
por: Han, Yue, et al.
Publicado: (2021)

Efficacy and Safety of Intensity-Modulated Radiotherapy Following Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma
por: Zhang, Tao, et al.
Publicado: (2016)

Plasma arginase-1 as a predictive marker for early transarterial chemoembolization refractoriness in unresectable hepatocellular carcinoma
por: Xia, Wei-Li, et al.
Publicado: (2022)

Drug-eluting beads versus conventional transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis
por: Wang, Zi-Yu, et al.
Publicado: (2023)

Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma
por: Kong, Jie-Yu, et al.
Publicado: (2018)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection
por: Chao, Jiashuo, et al.
Publicado: (2021)

Efficacy and Safety of Transarterial Chemoembolization with a Three-Stage Mixed Chemoembolic Regimen for Large Unresectable Hepatocellular Carcinoma
por: Yang, Yanjie, et al.
Publicado: (2023)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Transarterial Chemoembolization Followed by Radiotherapy Versus Sandwich Treatment for Unresectable or Ablative Hepatocellular Carcinoma
por: Lin, Haimin, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined With Endoscopic Therapy Is Beneficial for Unresectable Hepatocellular Carcinoma With Esophagogastric Varices
por: Tao, Ziwen, et al.
Publicado: (2021)

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
por: Ju, Shuguang, et al.
Publicado: (2022)

Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
por: Ma, Jun, et al.
Publicado: (2023)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin
por: Cui, Wei, et al.
Publicado: (2017)

Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis
por: Si, Tengfei, et al.
Publicado: (2022)

Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Jin-Xing, et al.
Publicado: (2022)

Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
por: Wang, Yan-Yu, et al.
Publicado: (2023)

Development and Validation of Nomograms to Predict the Prognosis of Patients With Unresectable Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
por: Zhao, Dongxu, et al.
Publicado: (2023)

Chinese herbal medicine, Jianpi Ligan decoction, improves prognosis of unresectable hepatocellular carcinoma after transarterial chemoembolization: a retrospective study
por: Tang, Cheng Wu, et al.
Publicado: (2016)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Weihua, et al.
Publicado: (2021)

Dynamic Nomogram for Predicting Macrovascular Invasion of Patients with Unresectable Hepatocellular Carcinoma after Transarterial Chemoembolization
por: Yan, Huiwen, et al.
Publicado: (2022)

Preoperative Versus Postoperative Transarterial Chemoembolization on Prognosis of Large Hepatocellular Carcinoma
por: Wang, Xiaohui, et al.
Publicado: (2021)

Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma
por: Zhong, Bin-Yan, et al.
Publicado: (2023)

Transarterial chemoembolization with pirarubicin-eluting microspheres in patients with unresectable hepatocellular carcinoma: Preliminary results
por: Bai, Mingjun, et al.
Publicado: (2019)

A Novel Pre-treatment Model Predicting Risk of Developing Refractoriness to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
por: Hu, Keshu, et al.
Publicado: (2020)

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2020)

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
por: Kudo, Masatoshi, et al.
Publicado: (2022)

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
por: Kloeckner, Roman, et al.
Publicado: (2015)

Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study
por: Zhu, Di, et al.
Publicado: (2022)

Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma
por: Jin, Zhi-Cheng, et al.
Publicado: (2021)

Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Li, Lin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4lq84jl7i3l85i3nikgh4d17t6